Testing a new medication for chronic lung disease

Plain-English translation of NCT06944925 on ClinicalTrials.gov ↗ · Source last updated May 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called to see if it is safe and works well for people with chronic obstructive pulmonary disease (COPD), a condition that makes it hard to breathe. The study will first test the medication in healthy volunteers at increasing doses, then move to patients with COPD. Researchers want to understand how the medication is processed by the body and whether it helps improve lung function.

COPD is a serious lung disease that affects millions of people and limits their ability to breathe and be active. This trial exists to find out if this new treatment could offer patients a better way to manage their disease and improve their quality of life.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old (if you are a healthy volunteer) or between 35 and 75 years old (if you have COPD)
you have been diagnosed with COPD with documented breathing test results showing reduced lung function
you have a body mass index between 18 and 32
you are willing to avoid alcohol for 24 hours before each study visit
you use adequate birth control if you are capable of becoming pregnant

You likely don't qualify if…

you have HIV, hepatitis B, or hepatitis C
you have an autoimmune disease, cancer, or a condition that weakens your immune system
you have significant liver, kidney, or heart disease
you have used drugs or alcohol regularly in the past 2 years
you have had a severe allergic reaction or serious allergy in the past

What participation looks like

If you join this trial, you will receive either the new medication or a placebo (a dummy treatment) across multiple visits over several weeks. Healthy volunteers will first receive a single dose, then in a second part receive three doses over time. If you have COPD, you will receive two doses of the medication or placebo. At each visit, you will have blood tests, breathing tests, and other check-ups to see how your body is responding to the treatment.

AI-generated summary from trial data · Jun 2, 2026 · Not medical advice

Trial locations(1 site)

Australia

Linear Clinical Research, Perth, Western Australia